Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SER 100

Drug Profile

SER 100

Alternative Names: SER-100; SER100 PH; SER100 TR-ISH; ZP-120

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Serodus; Zealand Pharma
  • Class Oligopeptides; Peptides
  • Mechanism of Action Nociceptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Isolated systolic hypertension
  • No development reported Pulmonary hypertension
  • Discontinued Decompensated heart failure

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for phase-I development in Pulmonary-hypertension(In volunteers) in Norway (IV, Infusion)
  • 16 Jan 2016 Phase-I clinical trials in Pulmonary hypertension (In volunteers) in Norway (IV) before January 2016
  • 09 Sep 2014 Efficacy and adverse events data from a phase IIa trial in Isolated systolic hypertension released by Serodus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top